文献速递其他结缔组织病

评估托法替布在干燥综合征中的治疗潜力:一项全面的临床与免疫学评估

Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

两项独立队列研究(回顾性队列I和前瞻性队列II)评估口服托法替布治疗干燥综合征的疗效、安全性和免疫学效应。队列I中112例患者ESSDAI评分显著改善;队列II中10例完成12个月治疗,第6个月ESSDAI较基线显著降低,80%(8/10)患者ESSPRI下降至少1分或15%,Th17细胞比例显著降低,Tfh和Tph细胞减少,未观察到严重不良事件。

要点

  • 队列I中112例患者托法替布治疗后ESSDAI评分显著改善(P < 0.001)。
  • 队列II中10例完成12个月治疗,第6个月ESSDAI较基线显著降低(P = 0.001)。
  • 80%(8/10)患者ESSPRI下降至少1分或15%,Th17细胞比例显著降低(P = 0.008)。

核心结论

  • 托法替布有效改善干燥综合征疾病活动度和免疫调节,并与抑制Tfh和Tph细胞相关,提示其作为治疗选择的潜力。

研究设计与样本

  • 两项独立队列研究:队列I为回顾性研究,队列II为前瞻性研究,评估口服托法替布治疗干燥综合征患者的疗效。
  • 所有参与者评估疾病活动度和实验室参数变化,并分析循环T细胞,重点关注滤泡辅助性T(Tfh)细胞和外周辅助性T(Tph)细胞。
  • 临床试验注册号:NCT05087589。

主要发现

  • 队列I中112例接受托法替布治疗的患者ESSDAI评分显著改善[中位数(IQR),8.00(4.25,15.75) vs 6.50(2.25,12.75),P < 0.001]。
  • 队列II中10例患者完成12个月治疗,第6个月ESSDAI评分较基线显著降低(P = 0.001)。
  • 队列II中80%(8/10)患者ESSPRI评分下降至少1分或15%。
  • 观察到Th17细胞比例显著降低(均值±SD,14.84 ± 7.70 vs 7.74 ± 4.24,P = 0.008)。
  • 观察到Tfh和Tph细胞减少,同时CD4+ T细胞中pSTAT-3水平及疾病活动度评分降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy, safety and immunological effects of tofacitinib in patients with Sjögren's disease (SjD), focusing on its impact on disease activity and immune cell modulation. METHODS: Two independent cohort studies, one retrospective (Cohort I) and one prospective (Cohort II), were conducted to investigate the efficacy of oral tofacitinib treatment in patients diagnosed with SjD. All participants were evaluated for changes in disease activity and lab parameters. Circulating T cells were analysed, focusing on follicular helper T (Tfh) cells and peripheral helper T (Tph) cells. RESULTS: In cohort I, 112 patients treated with tofacitinib showed a significant improvement in the ESSDAI score [median (IQR), 8.00 (4.25, 15.75) vs 6.50 (2.25, 12.75), P < 0.001]. In cohort II, ten patients completed the 12-month treatment period. There was a significant reduction in ESSDAI scores at the sixth month compared with baseline (P = 0.001). In total, 80% (8/10) of patients achieved a decrease of at least one point or 15% in ESSPRI scores. A significant reduction in the proportion of Th17 cells was observed (mean ± SD, 14.84 ± 7.70 vs 7.74 ± 4.24, P = 0.008). A decrease in Tfh and Tph cells was also observed, along with decreased pSTAT-3 levels in CD4+ T cells and disease activity scores. No serious adverse events were observed in the two cohorts. CONCLUSIONS: Tofacitinib effectively improves disease activity and immune regulation in SjD, and it is associated with suppressing Tfh and Tph cells, suggesting its potential as a treatment option. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05087589.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Liu Q, Zeng Y, Xing X, et al. Evaluating the therapeutic potential of tofacitinib in Sjögren's disease: a comprehensive clinical and immunological assessment. Rheumatology (Oxford). 2025. PMID: 40139690. doi:10.1093/rheumatology/keaf173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。